Page 3 - Karveer Meditech News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NanoViricides completes Phase 1 trial for respiratory viral infection candidate

NanoViricides completes Phase 1 trial for respiratory viral infection candidate
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

Karveer meditechDrug sponsor

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock

SHELTON, CT / ACCESSWIRE / April 30, 2024 / NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that the Phase I Clinical Trial of NV-387 is completed successfully and data lock is expected soon.The Phase 1 clinical trial, protocol number.

United statesKarveer meditechNirsevimab beyfortusNanoviricides incDevelopment towards regulatory approvalExchange commissionEuropean medicines agencySecurities exchangeNanoviricides platform technologyTheracour pharma incCommittee for medicinal products humanDrug administrationSobi incPhasei clinical trialDrug sponsorProtocol discussion

NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon

NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesTapparelc heparanEuropean medicines agencyCompany boardNanoviricides incExchange commissionNanoviricides platform technologySecurities exchangeCommittee for medicinal products humanTheracour pharma incCompany seriesDrug administrationDrug development statusQuarterly reportConduct clinicalIntangible assets

NanoViricides, Inc : NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon

NanoViricides, Inc : NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesStefan klotterTapparelc heparanExchange commissionNanoviricides incCompany boardEuropean medicines agencyCommittee for medicinal products humanSecurities exchangeNanoviricides platform technologyCompany seriesDrug administrationTheracour pharma incDrug development statusQuarterly reportConduct clinical

NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfu

SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarterly Report on Form 10-Q for the fiscal second quarter ending December 31, 2023 with the Securities and Exch.

United statesTapparelc heparanExchange commissionEuropean medicines agencyTheracour pharma incDrug administrationCommittee for medicinal products humanSecurities exchangeDrug development statusCompany boardNanoviricides incCompany seriesNanoviricides platform technologyQuarterly reportConduct clinicalIntangible assets